{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:23:10Z","timestamp":1761171790817,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":302,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.riam.2021.02.004","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T23:01:13Z","timestamp":1620860473000},"page":"52-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anfotericina B liposomal: farmacolog\u00eda cl\u00ednica, farmacocin\u00e9tica y farmacodinamia"],"prefix":"10.1016","volume":"38","author":[{"given":"Jos\u00e9 Ram\u00f3n","family":"Azanza Perea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2021.02.004_bib0200","unstructured":"Abelcet (anfotericina B complejo lip\u00eddico). Ficha t\u00e9cnica. Madrid: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios; 2020."},{"key":"10.1016\/j.riam.2021.02.004_bib0205","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006454-198906000-00030","article-title":"Amphotericin B in the treatment of Candida cholecystitis","volume":"8","author":"Adamson","year":"1989","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.riam.2021.02.004_bib0210","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","article-title":"Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase i and phase ii studies","volume":"41","author":"Adedoyin","year":"1997","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0215","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/AAC.44.10.2900-2902.2000","article-title":"A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections","volume":"44","author":"Adedoyin","year":"2000","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 5","key":"10.1016\/j.riam.2021.02.004_bib0220","first-page":"S3","article-title":"AmBisome targeting to fungal infections","volume":"14","author":"Adler-Moore","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.riam.2021.02.004_bib0225","first-page":"151","article-title":"In vitro and in vivo interactions of AmBisome with pathogenic fungi","volume":"3","author":"Adler-Moore","year":"1993","journal-title":"J Liposome Res."},{"issue":"Suppl 1","key":"10.1016\/j.riam.2021.02.004_bib0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience","volume":"49","author":"Adler-Moore","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2021.02.004_bib0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","article-title":"Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B","volume":"3","author":"Adler-Moore","year":"1993","journal-title":"J Liposome Res."},{"key":"10.1016\/j.riam.2021.02.004_bib0240","unstructured":"Ambisome (anfotericina B liposomal). Ficha t\u00e9cnica. Madrid: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios; 2020."},{"key":"10.1016\/j.riam.2021.02.004_bib0245","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0250","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","article-title":"Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model","volume":"45","author":"Andes","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","article-title":"Amphotericin B pharmacokinetics in humans","volume":"13","author":"Atkinson","year":"1978","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0260","first-page":"963","article-title":"Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.riam.2021.02.004_bib0265","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkh542","article-title":"Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signaling from TLR-2 to TLR-4","volume":"55","author":"Bellocchio","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0275","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.riam.2021.02.004_bib0280","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ajhp\/zxz054","article-title":"Apparent interference with extracorporeal membrane oxygenation by liposomal amphotericin B in a patient with disseminated blastomycosis receiving continuous renal replacement therapy","volume":"76","author":"Branick","year":"2019","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.riam.2021.02.004_bib0285","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis."},{"key":"10.1016\/j.riam.2021.02.004_bib0290","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.riam.2021.02.004_bib0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0079-6468(08)70148-6","article-title":"Biological activity of polyene antibiotics","volume":"14","author":"Hammond","year":"1977","journal-title":"Prog Med Chem."},{"issue":"Suppl 5","key":"10.1016\/j.riam.2021.02.004_bib0300","first-page":"S8","article-title":"Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations","volume":"14","author":"Heinemann","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.riam.2021.02.004_bib0305","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0169-409X(96)00496-6","article-title":"Supramolecular lipidic drug delivery systems: From laboratory to clinic. A review of the recently introduced comercial liposomal and lipid-based formulations of amphotericin B","volume":"24","author":"Hillery","year":"1997","journal-title":"Adv Drug Del Rev."},{"key":"10.1016\/j.riam.2021.02.004_bib0310","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2021.02.004_bib0315","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1128\/AAC.01586-09","article-title":"Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis","volume":"54","author":"Lestner","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0320","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00134-008-1269-3","article-title":"Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation","volume":"35","author":"Ruiz","year":"2009","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.riam.2021.02.004_bib0325","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2021.02.004_bib0330","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1128\/AAC.49.4.1397-1403.2005","article-title":"Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B","volume":"49","author":"Simitsopoulou","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0335","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/jac\/dkm077","article-title":"Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B","volume":"59","author":"Smith","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0340","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dku148","article-title":"Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B","volume":"69","author":"Strenger","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0345","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","article-title":"Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion","volume":"57","author":"Vogelsinger","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0350","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02383-17","article-title":"The viscoelastic properties of the fungal cell wall allow traffic of AmBisome as intact liposome vesicles","volume":"9","author":"Walker","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.riam.2021.02.004_bib0355","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2021.02.004_bib0360","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients","volume":"42","author":"Walsh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2021.02.004_bib0365","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/jac\/dkn306","article-title":"Levels of amphotericin B lipid formulations in ascites","volume":"62","author":"Weiler","year":"2008","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0370","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1128\/AAC.01087-07","article-title":"Penetration of amphotericin B lipid formulations into pleural effusion","volume":"51","author":"Weiler","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0375","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1128\/AAC.00796-09","article-title":"Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations","volume":"53","author":"Weiler","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0380","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijantimicag.2015.04.009","article-title":"Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations","volume":"46","author":"Welte","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.riam.2021.02.004_bib0385","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1128\/AAC.02535-14","article-title":"In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier","volume":"58","author":"Wu","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.02.004_bib0390","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/phar.2348","article-title":"Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation","volume":"40","author":"Zhao","year":"2020","journal-title":"Pharmacotherapy."}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:08:13Z","timestamp":1761106093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140621000218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1130140621000218"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2021.02.004","relation":{},"ISSN":["1130-1406"],"issn-type":[{"type":"print","value":"1130-1406"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anfotericina B liposomal: farmacolog\u00eda cl\u00ednica, farmacocin\u00e9tica y farmacodinamia","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2021.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda.","name":"copyright","label":"Copyright"}]}}